A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations

Summary: The novel betacoronavirus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) causes a form of severe pneumonia disease called coronavirus disease 2019 (COVID-19). To develop human neutralizing anti-SARS-CoV-2 antibodies, antibody gene libraries from convalescent COVID-19 patients...

Descrición completa

Detalles Bibliográficos

Principais autores:	Federico Bertoglio, Viola Fühner, Maximilian Ruschig, Philip Alexander Heine, Leila Abassi, Thomas Klünemann, Ulfert Rand, Doris Meier, Nora Langreder, Stephan Steinke, Rico Ballmann, Kai-Thomas Schneider, Kristian Daniel Ralph Roth, Philipp Kuhn, Peggy Riese, Dorina Schäckermann, Janin Korn, Allan Koch, M. Zeeshan Chaudhry, Kathrin Eschke, Yeonsu Kim, Susanne Zock-Emmenthal, Marlies Becker, Margitta Scholz, Gustavo Marçal Schmidt Garcia Moreira, Esther Veronika Wenzel, Giulio Russo, Hendrikus S.P. Garritsen, Sebastian Casu, Andreas Gerstner, Günter Roth, Julia Adler, Jakob Trimpert, Andreas Hermann, Thomas Schirrmann, Stefan Dübel, André Frenzel, Joop Van den Heuvel, Luka Čičin-Šain, Maren Schubert, Michael Hust
Formato:	Artigo
Idioma:	Inglês
Publicado:	Elsevier 2021-07-01
Series:	Cell Reports
Assuntos:	SARS-CoV-2 RBD spike protein neutralizing antibody recombinant antibody phage display
Acceso en liña:	http://www.sciencedirect.com/science/article/pii/S2211124721008500
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!